Nankai Hecheng Completes RMB 200 Million Series B Financing to Expand Leadership in Functional Polymer Resins

Recently,Tianjin Nankai Hecheng S&T Co., Ltd. (hereinafter referred to as “Nankai Hecheng”), a key global supplier of solid-phase synthesis carrier resins, has completed a RMB 200 million Series B financing round, led by Shenzhen Capital Group Co., Ltd. (SCGC). BMD-Capital served as the exclusive financial advisor for this round.The proceeds from this round of financing will be primarily used for subsequent capacity expansion by Tianjin Nankai Hecheng S&T Co., Ltd., as well as for the expansion and enhancement of the company’s talent team.

Tianjin Nankai Hecheng S&T Co., Ltd. was established in 2001 as a manufacturer of functional polymer resins with industry-leading R&D capabilities. The company currently offers a comprehensive product portfolio, including solid-phase synthesis carrier resins, adsorption resins, immobilized enzyme resins, hemoperfusion resins, ion exchange resins, and chromatographic separation resins. These products have been successfully applied in numerous fields, such as the solid-phase synthesis of peptide and small nucleic acid drugs, the separation and purification of peptides and proteins, and the semi-synthesis of antibiotic drugs, positioning the company as a core global supplier. Previously, Tianjin Nankai Hecheng secured investments from multiple institutions, including Honghui Fund, Sinochem Capital Venture Capital, Haihe Fund, BlueRun Ventures, CMB International Capital, Huajin Capital, and Bohai Chuangfu. Following this round of financing, the company will continue to leverage its foundation of efficient, stable, and high-quality large-scale production, while expanding its R&D and sales capabilities. Looking ahead, it aims to further consolidate and expand its presence in both domestic and international markets, striving to become a comprehensive leading enterprise in the global functional polymer resin sector.

SCGC Investment Team“The rapid expansion of the peptide drug market in recent years has created incremental opportunities for upstream raw material suppliers. Tianjin Nankai Hecheng S&T Co., Ltd. has been deeply engaged in the field of core upstream materials for many years and is a leading enterprise in functional polymer resins with top-tier R&D capabilities. We are highly optimistic about Nankai Hecheng’s platform-based technology application capabilities and its ability to rapidly scale up supply. The recent surge in market volume driven by peptide drugs, along with its significant growth potential in future sectors such as biopharmaceuticals, environmental protection, and new energy, underscores its promising outlook.”

Mr. Yang Hao, Founder and Managing Partner of BMD-Capitalstated: “In recent years, peptide drugs have achieved significant development and breakthroughs globally, becoming one of the most promising niche segments in the biopharmaceutical industry. We believe that Tianjin Nankai Hecheng S&T Co., Ltd., as a core raw material supplier for peptide drug synthesis, possesses strong technical capabilities and extensive experience in resin development. The company demonstrates robust industry competitiveness in both product quality and cost efficiency, while also holding a distinct advantage in its leading domestic and international capacity for large-scale product supply. BMD-Capital is honored to have assisted Tianjin Nankai Hecheng S&T Co., Ltd. in successfully completing this round of financing. We will work hand in hand with the enterprise to actively promote the development of new-quality productive forces.”

Previous-round investor BlueRun Ventures“It is stated that solid-phase synthesis is currently one of the mainstream production methods for peptides. Novel resins can enhance peptide production efficiency by providing higher amino acid coupling conversion rates. Meanwhile, their excellent mechanical properties and chemical stability can optimize reaction conditions, improve the purity of the resulting peptides, and ultimately elevate the quality of peptide drugs. Tianjin Nankai Hecheng S&T Co., Ltd. has been deeply engaged in the field of functional polymers for decades and possesses top-tier R&D capabilities. As the peptide industry stands at a turning point driven by both supply and demand, we are optimistic about the development potential of Tianjin Nankai Hecheng.”

Shenzhen Capital Group Co., Ltd. (SCGC) was established in 1999 with capital contributed by the Shenzhen Municipal Government, which also guided investments from social capital. With the mission of “Discovering and Empowering Great Enterprises,” the company is committed to identifying and nurturing innovative value. It has since evolved into a comprehensive investment group centered on venture capital, managing total assets under management exceeding RMB 480 billion. The SCGC Manufacturing Transformation and Upgrading New Materials Fund serves as a dedicated investment vehicle for the National Manufacturing Transformation and Upgrading Fund, focusing primarily on investments in the new materials sector.

BMD-Capital is a leading financial services institution in China, specializing in the healthcare and wellness sector. Its team comprises seasoned industry experts and professional investment bankers with deep insights into the medical industry and business models, enabling them to navigate the complexities and structural challenges inherent in transactions. The firm provides specialized capital solutions for clients, including financing, mergers and acquisitions, and technology transfers.

BlueRun Ventures is a leading early-stage technology investment firm in China, dedicated to supporting entrepreneurs who dare to redefine the future through technology. It is currently one of the largest early-stage funds in the country. BlueRun Ventures focuses its investments on the Pre-A and Series A stages, with coverage spanning artificial intelligence, hard tech, consumer tech, biotechnology, and other sectors. Having invested in over 200 startups, the firm provides long-term support to entrepreneurs from the early stages onward.